The testing hall gets bigger
Phase 3 · 2023–2026
Can the early promise survive bigger trials?
Subject One reaches a much larger hall. There are desks for glucose, weight and aching knees. His “exceptional candidate” badge suddenly feels very small. Doctide gives him a chair. “We need enough evidence to see what one person cannot.”
What changes here
Larger trials tested glucose, weight and knee-pain questions. Their safety records mattered just as much as their headline results. [1] [2]
Read the study details & dates
TRIUMPH expands the questions
Lilly’s TRIUMPH-4 report described 445 adults with obesity or overweight and knee osteoarthritis over 68 weeks. It reported weight and pain improvements, but also gastrointestinal effects, altered skin sensations and treatment discontinuations. This checkpoint uses a sponsor report. [1]
TRANSCEND-T2D-1
A 40-week Phase 3 trial enrolled 537 people with type 2 diabetes inadequately controlled by diet and exercise. It reported improved glucose and weight outcomes. The safety record belongs beside those results. [2]
What this does not establish
Study size alone does not remove uncertainty. Different analyses can produce different weight-loss estimates; compare like populations, timepoints and estimands rather than picking the largest headline.
Original sources
- Lilly TRIUMPH-4 announcement, December 11, 2025 (sponsor)
- Bajaj et al., TRANSCEND-T2D-1 primary publication
Sources reviewed 2026-10-11. Study and publication dates are stated separately where known.
Subject One is fictional. Separate studies, species and populations are not a single patient’s experience. How to read the story